Treatment Tactics for Psychosis in Parkinson’s Disease: A Literature Review
Parkinson’s disease is a neurodegenerative disorder which leads to a progressive disability. The loss of dopaminergic neurons and disturbances in their connections cause deficient signaling of dopamine circuits, which results in motor and non-motor symptoms. Cognitive and behavioral disturbances ar...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Vilnius University Press
2024-12-01
|
| Series: | Neurologijos seminarai |
| Subjects: | |
| Online Access: | https://ojs.test/index.php/neurologijos_seminarai/article/view/38295 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841561156360077312 |
|---|---|
| author | Daiva Milmantienė |
| author_facet | Daiva Milmantienė |
| author_sort | Daiva Milmantienė |
| collection | DOAJ |
| description |
Parkinson’s disease is a neurodegenerative disorder which leads to a progressive disability. The loss of dopaminergic neurons and disturbances in their connections cause deficient signaling of dopamine circuits, which results in motor and non-motor symptoms. Cognitive and behavioral disturbances are also common, including the possible onset of psychotic symptoms. Data on the prevalence of psychosis, caused by Parkinson’s disease is limited, as diagnostic criteria are not universally applied. Modified NINDS (National Institute of Neurological Disorders and Stroke) criteria can be used. Several scales have been developed to assess the risk of psychosis development, to confirm the diagnosis, and to evaluate the symptom severity. For reliable diagnosis, it is advisable to use multiple scales, considering individual patient symptoms and differential diagnoses. Pharmacological treatment may include antipsychotics (quetiapine, clozapine), dopamine D2 receptor antagonists, 5-HT2A receptor ligands, medications for dementia, anxiolytics, antidepressants, and gabapentin. Non-pharmacological treatment may include electroconvulsive therapy, deep brain stimulation, and transcranial direct current stimulation. Use of treatment algorithms is recommended. Further research is necessary to discover new drugs specifically targeting the treatment of this disorder. Although Lithuania does not yet provide access to Pimavanserin, a drug specifically indicated for psychosis associated with Parkinson’s disease, other treatments can be recommended for patients, along with psychological counseling and collaboration with psychiatrists and psychologists.
|
| format | Article |
| id | doaj-art-fbc84c7e0f6848218901ff9b1098fe34 |
| institution | Kabale University |
| issn | 1392-3064 2424-5917 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Vilnius University Press |
| record_format | Article |
| series | Neurologijos seminarai |
| spelling | doaj-art-fbc84c7e0f6848218901ff9b1098fe342025-01-03T06:38:27ZengVilnius University PressNeurologijos seminarai1392-30642424-59172024-12-01281(99)10.15388/NS.2024.28.99.4Treatment Tactics for Psychosis in Parkinson’s Disease: A Literature ReviewDaiva Milmantienė0Vilnius University, Lithuania Parkinson’s disease is a neurodegenerative disorder which leads to a progressive disability. The loss of dopaminergic neurons and disturbances in their connections cause deficient signaling of dopamine circuits, which results in motor and non-motor symptoms. Cognitive and behavioral disturbances are also common, including the possible onset of psychotic symptoms. Data on the prevalence of psychosis, caused by Parkinson’s disease is limited, as diagnostic criteria are not universally applied. Modified NINDS (National Institute of Neurological Disorders and Stroke) criteria can be used. Several scales have been developed to assess the risk of psychosis development, to confirm the diagnosis, and to evaluate the symptom severity. For reliable diagnosis, it is advisable to use multiple scales, considering individual patient symptoms and differential diagnoses. Pharmacological treatment may include antipsychotics (quetiapine, clozapine), dopamine D2 receptor antagonists, 5-HT2A receptor ligands, medications for dementia, anxiolytics, antidepressants, and gabapentin. Non-pharmacological treatment may include electroconvulsive therapy, deep brain stimulation, and transcranial direct current stimulation. Use of treatment algorithms is recommended. Further research is necessary to discover new drugs specifically targeting the treatment of this disorder. Although Lithuania does not yet provide access to Pimavanserin, a drug specifically indicated for psychosis associated with Parkinson’s disease, other treatments can be recommended for patients, along with psychological counseling and collaboration with psychiatrists and psychologists. https://ojs.test/index.php/neurologijos_seminarai/article/view/38295Parkinson’s diseasenon-motor symptomspsychosisdopamine antagonists |
| spellingShingle | Daiva Milmantienė Treatment Tactics for Psychosis in Parkinson’s Disease: A Literature Review Neurologijos seminarai Parkinson’s disease non-motor symptoms psychosis dopamine antagonists |
| title | Treatment Tactics for Psychosis in Parkinson’s Disease: A Literature Review |
| title_full | Treatment Tactics for Psychosis in Parkinson’s Disease: A Literature Review |
| title_fullStr | Treatment Tactics for Psychosis in Parkinson’s Disease: A Literature Review |
| title_full_unstemmed | Treatment Tactics for Psychosis in Parkinson’s Disease: A Literature Review |
| title_short | Treatment Tactics for Psychosis in Parkinson’s Disease: A Literature Review |
| title_sort | treatment tactics for psychosis in parkinson s disease a literature review |
| topic | Parkinson’s disease non-motor symptoms psychosis dopamine antagonists |
| url | https://ojs.test/index.php/neurologijos_seminarai/article/view/38295 |
| work_keys_str_mv | AT daivamilmantiene treatmenttacticsforpsychosisinparkinsonsdiseasealiteraturereview |